結論
BNCT has been investigated rigorously to expand additional malignancies. It is well-known that BNCT can be applied to breast cancer, and we performed BNCT for patients with recurrent breast cancer after radiation therapy. This study is a significant milestone as the first application of AB-BNCT for breast cancer treatment. The average dose of the ipsilateral lung was 5 Gy-Eq at maximum in this study. In all cases, there was no incidence of radiation pneumonitis within 90 days. While long-term observation is still necessary, these findings indicate the potential applicability of BNCT for the treatment of thoracic regions.
結論
BNCT has been investigated rigorously to expand additional malignancies. It is well-known that BNCT can be applied to breast cancer, and we performed BNCT for patients with recurrent breast cancer after radiation therapy. This study is a significant milestone as the first application of AB-BNCT for breast cancer treatment. The average dose of the ipsilateral lung was 5 Gy-Eq at maximum in this study. In all cases, there was no incidence of radiation pneumonitis within 90 days. While long-term observation is still necessary, these findings indicate the potential applicability of BNCT for the treatment of thoracic regions.
BNCTは、追加の悪性腫瘍を拡大するために厳密に調査されています。BNCTが乳がんに適用できることはよく知られており、放射線療法後に再発乳がん患者にBNCTを実施しました。この研究は、乳がん治療のためのAB-BNCTの最初の適用として重要なマイルストーンです。この研究では、同側肺の平均線量は最大で5Gy-Eqでした。いずれの場合も、90日以内に放射線肺炎の発生率はなかった。長期的な観察はまだ必要ですが、これらの知見は、脛部の治療に対するBNCTの潜在的な適用可能性を示しています。